All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Patients with newly diagnosed multiple myeloma (NDMM) who experience an incomplete response to autologous stem cell transplantation (ASCT) have poorer outcomes, with an increased risk of progression (38%) and an increased risk of death (41%) compared with patients who experience a complete response.1 KarMMa-9 (NCT06045806) is an ongoing phase III trial comparing the efficacy and safety of idecabtagene vicleucel (ide-cel) plus lenalidomide for maintenance vs lenalidomide alone in patients with NDMM who had a suboptimal response (partial response or very good partial response) to ASCT.
Here we summarize a poster presentation by Mateos, et al.1 from the 5th European Myeloma Network Meeting, 2024, on the rationale and study design of the phase III KarMMa-9 trial.1
Figure 1. KarMMa-9 study design*
CAR, chimeric antigen receptor; ide-cel, idecabtagene vicleucel; LDC, lymphodepleting chemotherapy; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
*Adapted from Mateos, et al.1
†Apheresis to be performed within 14−42 days after last dose of R.
‡Fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 on Days -5, -4, and -3 prior to ide-cel infusion.
Key learnings1 |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox